Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen to Provide Real-Time PCR Services Based on Exiqon's miRNA Assay Product

Premium

Exiqon and Asuragen said this week that they have signed a service center agreement that allows Asuragen to provide real-time PCR services based on Exiqon's MiRcury LNA Universal RT microRNA PCR products.

Asuragen's genomic services division provides a comprehensive range of nucleic acid-based services from biomarker discovery to development of companion diagnostics, including isolation and preparation from multiple sample types, genomic profiling, miRNA/mRNA expression profiling, assay development and validation, CLIA-based clinical trial testing, bioinformatics, and regulatory services.

Exiqon's LNA-based microRNA real-time PCR profiling combines a Universal RT reaction with locked nucleic acid-enhanced PCR primers, which results in a high degree of sensitivity and specificity for all sample types, the company said. The assay system "holds great promise as a non-invasive way to discover important new biomarkers for a wide range of diseases and biological processes," Exiqon said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.